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1. Introduction  
Osteosarcoma is a very rare malignant bone tumor with an incidence of 4-6 cases in 
1,000,000 inhabitants and appears mostly in the young and active population aged 10- 30 
years (Price & Jeffree, 1977). Amputations and disarticulations as dominant treatment for 
malignant bone tumors in the beginning of 20th century are rarely and very selectively used 
today. Before 1970, amputation was the primary treatment for high-grade osteosarcoma and 
80% of patients died of lung metastatic disease. Despite aggressive and radical surgery, 5-
year survival was low (10-20%) (Rosen et al., 1976). Introducing new sophisticated 
diagnostic methods (CT and MRI) gave the possibility of precise anatomic definition of the 
tumors and the borders of infiltration into the surrounding tissues. Better planning of the 
biopsy and the definite operative procedure, and fostering better patient selection for 
specific treatment strategies, can decrease the risk of tumor spread into the surrounding 
tissue and lower the risk of distant metastases. After 1980, improvement of 
chemotherapeutic protocols with neoadjuvant chemotherapy, better preoperative planning 
and modern reconstructive options after resection of osteosarcoma led to better survival 
rates of patients with limb-sparing procedures (Bacci et al., 1993, Bruland & Phil, 1999).  
Currently, 80 - 85% of the patients with osteosarcoma on the extremities can be safely 
treated with wide resection and limb preservation (Di Caprio et al., 2003). A 
multidisciplinary approach to diagnosis and treatment, combination chemotherapy and a 
number of options for reconstruction after osteosarcoma resection (especially in 
chemotherapy-sensitive tumors) have increased long-term survival rates from 60 to 80%. 
Amputations, once a dominant treatment for malignant bone tumors, now are rarely and 
very selectively used. Most patients with extremity-localized osteosarcoma are candidates 
for limb-sparing procedures because of the: effective chemotherapeutic agents and 
regimens, the improved imaging modalities, and advances in reconstructive surgery. 
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Application of neoadjuvant chemotherapy improves survival rates and functional 
outcome in patients with non-metastatic, high-grade osteosarcoma of the extremities 
(Wittig et al., 2002).  
Before consideration of limb preservation, the patient needs to be appropriately staged and 
assessed through a multidisciplinary approach. Some elements of the disease may warrant 
concern, including relative contraindications to such procedures. However, surgical 
treatment associated with a limb-sparing operation is also associated with a significant 
number of complications and requires extensive rehabilitation. The main risk of limb-
salvage procedures is that complications sometimes may cause a delay of chemotherapy 
(Sæter al., 1996). 
2. Osteosarcoma subtypes and characteristics  
Depending on cytological or histo-pathological features of the tumor matrix or tumor cells, 
osteosarcomas are divided into two groups. In the first group there are patients with low-
grade osteosarcoma and surgery alone has the primary role of treatment. In the second group 
there are patients with high-grade osteosarcoma. In this group of patients “sandwich therapy” 
is strongly preferred (neoadjuvant chemotherapy - surgery - adjuvant chemotherapy) 
(Enneking, 1975; Bacci et al., 1993; Messerschmitt et al., 2009). 
2.1 Intramedullary osteosarcoma 
Conventional or “classic” osteosarcoma is the most prevalent type in children and adolescents 
(up to 80% of all cases). This type of osteosarcoma originates from the intramedullary cavity 
and is typically high-grade (Fig. 1a). An osteoblastic and/or osteolytic lesion with vast 
cortical destruction and various amount of soft tissue extension dominates on X-rays. Histo-
pathologic examination demonstrates malignant mesenhimal cells, spindle to polyhedral in 
shape, with pleomorphyc nuclei and occasional mitotic figures. Evidence of direct bone or 
osteoid production from the mesenhim is crucial for diagnosis (Fig. 1b, 1c). World Health 
Organization has further subcategorized high-grade intramedullary osteosarcoma since 
2002, depending on the predominant extra cellular matrix on: osteoblastic (approximately 
50% of cases), chondroblastic (25% of cases) or fibroblastic (25% of cases). (Fletcher et al., 2002).  
Teleangiectatic osteosarcoma is a rare variant accounting for approximately 4% of all 
osteosarcoma cases in children and adolescents. Very often they are associated with 
pathological fracture of the first presentation. Eccentric osteolytic lesion on the metaphysis, 
with destruction and expansion of the eroded cortex dominates on x-ray (Fig. 1b). Histo-
pathologic examination reveals a malignant tumor with multiple dilated hemorrhagic 
sinuses as well as a scarce amount of high-grade osteosarcoma cells and rare osteoid 
formation within the septa. These radiographic and histo-pathologic features resemble an 
aneurismal bone cyst which is cdaracteristic.  
Low-grade intramedullary osteosarcoma constitutes 1 to 2% of all osteosarcoma cases and 
generally affects patients in the third or fourth decade. Lesions most commonly affect the 
distal femur and proximal tibia, with relatively unaggressive radiographic appearance, 
resembling fibrous dysplasia (“fibrous dysplasia-like” osteosarcoma). Histo-pathological 
features consist of well-differentiated cells dispersed within woven microtrabeculae of bone 
and fibrous stroma. Small amounts of osteoid, mitotic atypia and mitoses can also be seen 
(Fletcher et al., 2002). 
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Small-cell osteosarcoma is a rare variant constituting <1.5% of all osteosarcoma cases. This 
subtype is similar to the high-grade osteosarcoma, with the same site or age distribution and 
aggressive biologic behavior. The lesion is osteolytic with destruction of cortex and variable 
sclerosis. MRI reveals large spindle or circumferential tumor mass, similar to Ewing 
sarcoma. Small, round, malignant cells within an osteoid matrix make the histo-pathological 
diagnosis problematic. To differentiate this osteosarcoma from Ewing sarcoma, direct 
mesenhimal production of osteoid must be found, because this osteosarcoma is positive for 
CD 99 immuno-histochemical stains (Fletcher et al., 2002).  
 
    
                      a)           b)   
    
               c)    d)   
 
Fig. 1. a) X-ray of conventional intramedullary osteosarcoma (osteoblastic lesion with vast 
cortical destruction and soft tissue edema visible on x-rays); b) X-ray of teleangiectatic 
osteosarcoma with osteolytic lesion on the metaphysis of distal femur, destruction, 
expansion of the eroded cortex and Codman’s periosteal reaction (arrow); c) Typical histo-
pathological feature of osteosarcoma is osteoid formations directly from the mesenhime; d) 
Atypical osteoid formation in high-grade anaplastic osteosarcoma typifies the diagnosis. 
A few osteosarcomas (less than 1% of all cases) have so many giant cells that they can be 
mistaken for giant cell tumors. Cytological atypia of the mononuclear cells can be very 
subtle and rare. It is important to remember the possibility of a giant cell-rich osteosarcoma 
when giant cell tumor-like lesion occurs in an unusual location and age, such as the 
metaphysis in children (Unni, 1998). 
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2.2 Surface osteosarcoma 
Parosteal osteosarcoma arises on the outer surface of the long bone metaphysis, sparing the 
medullary canal (Fig. 2a). The peak incidence is in the second and third decade, affecting 
more females than males.(10) Parosteal osteosarcoma is most commonly seen as a 
juxtracortical variety and constitutes 1 to 6% of all osteosarcoma cases. Radiographs 
classically show densely ossified and lobulated mass on the posterior surface of the femur. 
Sometimes slow-growing tumors may encircle the bone. A low-grade, well differentiated 
fibrous stroma with osseous components is regularly seen on the histo-pathologic 
examination. Parallel orientation of trabeculae with additional cartilaginous differentiation 
is very common (Fig. 2d). 
 
    
a)    b) 
   
             c)           d) 
 
Fig. 2. a) Frontal and lateral x-ray of the periosteal osteosarcoma of right distal femur; b) X-ray 
in frontal and lateral view of parosteal osteosarcoma of the proximal tibia; c) Frontal and 
lateral x-ray of high-grade surface osteosarcoma on the right distal femur; d) Parosteal 
osteosarcoma showing parallel osteoid trabeculae embedded in fibroblastic stroma (HE, x100). 
Periosteal osteosarcoma constitutes 1 to 2% of all osteosarcoma cases and is usually more 
aggressive than the parosteal variant. A radiolucent lesion is located on the distal femur 
or proximal tibia, sparing the medullar cavity (Fig. 2b). Codman triangle and “sunburst” 
periosteal reaction are common radiographic features. Histo-pathologic evaluation 
demonstrates an intermediate-grade tumor, rich with cartilaginous matrix and rare 
osteoid fields. 
High-grade surface osteosarcoma constitutes <1% of all osteosarcomas with the predominant site 
around the knee. Radiographic analysis shows surface lesion with partial mineralization 
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and tumor extension into surrounding soft tissues. In earlier stages of the disease, 
destruction of the underlying cortex is absent, but with advanced lesions involvement of the 
medullary cavity is possible (Fig. 2c). The histological features are those of high-grade 
osteosarcoma, demonstrating spindle cells with atypia and a varying amount of osteoid. A 
high-grade surface osteosarcoma cannot be differentiated from a conventional osteosarcoma 
in histological findings alone (Fletcher et al., 2002; Samardziski et al., 2009). 
3. Imaging 
There are various radiological imaging techniques available to achieve an accurate diagnosis 
and staging of osteosarcoma and to detect local recurrence or distant metastases. Most 
commonly used are: plain-film radiographs (as “gold” standard), Tc-99m bone scintigrapy, 
CT of the affected site or of the lungs and CT or conventional angiography. Positron 
emission tomography (PET-scan) and Thallium scintigraphy have been seldom used due to 
questionable results in evaluating early osteosarcoma metastases or due to their high-cost 
(Messerschmitt et al., 2009). 
 
 
            
 
             a)      b) 
 
Fig. 3. a) X-ray in two orthogonal planes of typical mixed sclerotic end lytic osteosarcoma of 
the distal femur. Tumor has penetrated bone and formed a soft tissue mass with Codman’s 
triangles. b) Frontal plane X-ray of osteosarcoma situated on proximal humerus with small, 
confluent cloud-like densities, destroing the bone completely. 
Plain-film radiographs in two ortogonal plains show mixed osteosclerotic and osteolytic 
tumor, affecting the metaphysis of the bone (although primarily sclerotic or lytic 
osteosarcomas can occur). The lesion is ill defined from the surrounding bone, affecting 
and destroing the cortex, with typical small, irregular, confluent, cloud-like densities. If 
the cortex is completely eroded the lesion forms a soft tissue mass extruding from the 
bone into the surrounding tissue and may demonstrate ossification detectable on the 
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radiographs (Fig. 3). The destruction may be so advanced that pathological fractures or 
complete bone erosion could be present (Fig. 3b). There is a typical periosteal reaction due 
to aggressive expansion of the tumor, forming hairy, sun-ray or velvet-like specula of 
neoplastic bone. In some cases “Codman’s triangles” (arrows on Fig. 3a) are present. 
Plain-film radiographs are used in correlation with bone scintigraphy and CT to detect 
local recurrence or bone and lung metastases. Additional data for diagnosis and decision-
making process can be obtained using a “computer assisted diagnosis” in analysis of the 
x-rays (Lodwick et al., 1963; Samardziski et al., 2004). 
Computer tomography (CT) scann of the affected extremity is useful in visualization of the 
intra and extra-osseous extent of the tumor, especially when extensive necrosis and 
surrounding edema are present. In this case CT may be superior to MRI. High-definition CT 
scans can obtain a three dimensional view of the tumor in relation to adjacent neurovascular 
structures, especially when contrast medium is used (Fig. 4a). All patients with 
osteosarcoma should undergo CT scanning of the chest and lungs for detection of 
pulmonary metastases, for diagnosis and staging. After surgery has been performed in 
patients with non-metastatic osteosarcoma, CT scans of the lung should be repeated every 
three to six months for two years (Wittig et al., 2002). 
 
 
   
        a)     b) 
 
Fig. 4. a) CT scans of proximal femur osteosarcoma, with visualization of the superficial and 
deep femoral artery b) T2-weighted MRI image of distal femur osteosarcoma with no extra-
osseous extension.  
With magnetic resonance imaging (MRI), standard T1 and T2-weighted and fat-suppressed 
images are obtained to visualize the affected bone and surrounding tissue with 
osteosarcoma. Based on MRI studies, the intra-osseous and extra-osseous extent of the 
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tumor is visible as well as reactive zone and tissue edema (Fig. 4b). Neurovascular 
structures and especially neurovascular encasement can be determined and it can help in 
the process of planning the definite method of treatment. (If encasement is present, 
amputation or wide resection with vascular reconstruction is obligatory).  
Obtaining an MRI prior to surgical resection permits accurate planning of the osteotomy 
and gross tumor excision (together with the reactive zone) for achieving a “wide” surgical 
margin. Skip metastases on MRI are easily detectable in the same bone or in the adjacent 
joint and then a more extensive resection is required. MRI studies are inferior to high-
definition CT scans for lung metastases detection (Di Caprio & Friedlander, 2003, 2003). 
4. Biopsy and histo-pathological diagnosis  
In spite of the risk for tumor spreading, biopsy is the key step in the diagnosis and treatment 
of osteosarcoma. Improperly performed biopsy may compromise the treatment plan. It is 
mandatory to place the biopsy in the line of definite surgical approach for osteosarcoma 
resection. A specimen taken from the necrotic tissue or from reactive zone (around the 
osteosarcoma) may be non informative. A large needle biopsy is sometimes preferable, 
because it is less invasive, with lower risk for skin necrosis, infection and pathological 
fracture. If no representative osteosarcoma tissue is obtained, an open biopsy will increase 
the risk of complications or local spreading of the tumor. The best results are achieved when 
all the biopsy samples are obtained by the same orthopedic oncologist (surgeon) who will 
perform the definite surgical procedure (Mankin et al., 1982; Campanacci, 1999). One must 
state that obtaining an accurate histo-pathological diagnosis of the tumor (especially of 
osteosarcoma) may be very delicate task (Fletcher et al. 2002). 
 
 
Stadium Grade Localisation Metastases 
IA G1 - Low-grade T1 - Intraosseus M0 - No metastases 
IB T2 - Extraosseus M0 - No metastases 
IIA  
G2 - High-grade 
T1 - Intraosseus M0 - No metastases 
IIB T2 – Extraosseus M0 - No metastases 
IIIA G1-2 T1 - Intraosseus M1 - With metastases 
IIIB G1-2 T2 - Extraosseus M1 - With metastases 
 
Table 1. Enneking’s surgical staging system: G1-Low-grade; G2-High-grade; T1-Intraosseus; 
T2-Extraosseus; M0-No metastases; M1-With metastases. 
5. Staging 
The American National Comprehensive Cancer Network recommends plain radiographs of 
the lesion and lungs, MRI scan of the extremity, CT scan of the tumor site and of the lungs, 
and radionuclide bone scan. Technetium Tc-99 methylene diphosphonate scintigraphy will 
reveal increased metabolic activity at the site of the tumor, but also at the site of distant skip 
or bone metastases. Thallium (Tl-201) is a potassium analog, actively transported by the 
sodium-potassium adenosine triphosphatase (ATP) pump. This radioisotope is well 
accumulated in benign or malignant tumors, reflecting tumor activity. Nevertheless, 
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Thallium scanning is mostly used for monitoring the response to neoadjuvant 
chemotherapy (especially when MRI is not helpful).  
Osteosarcoma can be divided into high-grade or low-grade variants, depending of 
cellularity, pleomorphism, anaplasia and number of mitoses (Fletcher et al. 2002). This fact 
and the data for presence or absence of osteosarcoma metastases will be enough to do the 
Enneking’s surgical staging (Table 1). This staging system, first used by the American 
Musculoskeletal Tumor Society and International Symposium on Limb-Salvage is widely 
accepted. An alternative system, established by the American Joint Committee on Cancer, 
can be used with Enneking’s staging system (Enneking et al., 1980). 
6. Treatment  
A multidisciplinary approach is obligatory in the diagnosis and treatment of 
osteosarcoma. To achieve high standards in treatment there is a need for specialized 
radiologists, pathologists, orthopedic and other surgeons (specialized in oncology 
surgery), pediatric oncologists, specialized physical therapist and often social workers 
(Wittig et Al., 2002). When a proper chemotherapy and surgery protocol are followed, 
survival rates surpass 70%. High-grade osteosarcoma patients without clinically 
detectable lung metastases are presumed to have micro metastases. For these patients 
treatment consists of preoperative (neoadjuvant) chemotherapy, wide or radical surgical 
resection and postoperative (adjuvant) chemotherapy i.e. “sandwich therapy”. Parosteal 
osteosarcoma or low-grade intra-medullar osteosarcoma patients are treated with wide or 
radical surgical resection alone. Chemotherapy is reserved only for cases with high-grade 
transformation. Periosteal osteosarcoma patients may be treated with preoperative 
(neoadjuvant) chemotherapy similar to that used for conventional osteosarcomas (Bacci et 
al., 1993; Bruland & Phil, 1999). 
6.1 Chemotherapy 
Advances in poly-chemotherapy protocols in the last 30 years have been responsible for 
improved survival rates and a possibility for limb salvage surgery. Since the beginning of 
the “odyssey” with Rosen and Jaffe, until now, chemotherapy has been shown to reduce the 
number of pulmonary metastases or to delay their appearance, facilitating surgical 
treatment (Rosen et al., 1976).  
Standard modern regimens include drugs that have been shown to be the most effective 
against osteosarcoma: doxorubicin (Adriamycin), cisplatin (Platinol) ifosfamide (Ifex) with 
mesna (Mesnex) and high-dose methotrexate (Rheumatrex) with Leucoverin calcium rescue. 
Most standard protocols use doxorubicin and cisplatin with or without high-dose 
methotrexate for both neoadjuvant (preoperative) and adjuvant (postoperative) 
chemotherapy. The postoperative (adjuvant) chemotherapy is mostly dependent on the 
extent of tumor necrosis evaluated after surgical removal. The postoperative chemotherapy 
regimen is typically the same as the preoperative regimen when tumor necrosis is found to 
be ≥ 90% at the time of surgery. “Poor responders” to preoperative chemotherapy, defined 
as those with <90% tumor necrosis at the time of surgery, may benefit from postoperative 
chemotherapy. In these patients a salvage therapeutic regime is attempted with an increased 
dose of chemotherapy, an increased length of chemotherapy, or a change in 
chemotherapeutic agent. Recent trials have incorporated ifosfamide after conventional 
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chemotherapeutic drugs to improve patient survival rates (Jaffe et al., 1989; Sæter et al., 
1996; Bacci et al., 2001; Messerschmitt et al., 2009). 
6.2 Surgery 
The two primary surgical options are tumor resection with limb-salvage, and amputation. 
Surgical margins in excision should encompass resection of tumor, pseudo capsule, and a 
cuff of normal tissue en block. Meticulous preoperative planning before the biopsy and 
definitive surgery will ensure better results. Prior to the emergence of limb-salvage surgery 
in the 1970s, amputation of the affected limb was considered the definitive surgical 
intervention. Amputation remains the indicated treatment when disease-free marginal 
resection leaves a nonfunctional limb.  
The limb-salvage surgery for osteosarcoma patients is possible due to the use of 
preoperative (neoadjuvant) chemotherapy and to advancement in musculoskeletal imaging, 
prosthetic implant design and surgical technique (Fig. 5). Today limb sparing surgery is 
possible for >85% of patients with extremities localized osteosarcomas (Bacci et al., 2006; Di 
Caprio & Friedlander, 2003; Longhi et al., 2006). 
Surgical treatment has to be planed keeping in mind four basic principles of limb-salvage 
procedures: local recurrence should be no greater and survival no worse than by 
amputation; the procedure, or treatment of its complications, should not delay adjuvant 
therapy; reconstruction should be enduring and not associated with a large number of local 
complications requiring secondary procedures and frequent hospitalizations; function of the 
limb should approach that obtained by amputation, although body image, patient 
preference and life style may influence the decision (González-Heranz et al. 1995).  
There are a few relative contraindications to be taken in the consideration for limb-salvage 
surgery: wrong site or ill-planed biopsy; massive encasement of neurovascular bundles; 
extensive tumour involvement in soft tissue, muscles or skin; complex or complicated (i.e. 
with infection) pathological fractures; expected inequalities of the extremities more than 8 
cm; and exceptionally poor effect of the neoadjuvant chemotherapy. In the process of 
decision making for limb-salvage surgery versus amputation the “rule of three” can be very 
helpful. For extremity survival the bone (1), nerves (2), blood vessels (3), and muscle and 
skin (4) are necessary to be preserved. If osteosarcoma involves one or two of the former 
structures, limb preserving is possible. If any three of the former are involved, amputation 
must be taken in consideration (Di Caprio & Friedlander, 2003). 
When “negative” tumor margins are obtained, a large skeletal defect is often present, 
requiring reconstruction of the bone, muscles, other soft tissues, and the skin. Patient age, 
tumor location and extent of resection, determine the appropriate surgical alternatives. The 
extent of the disease, anatomical location of the tumor and the patient’s age and 
psychological profile define the most appropriate surgical procedures. Several options for 
limb-sparing are available: resection arthrodesis and other similar techniques with special 
indications (Fig. 7c), modular or special expanding endoprostheses (Fig. 5), cortico-
spongious or bulk auto graft.  
For the patients who can’t satisfy the principles of limb preservation, ablative surgery has 
to be taken into consideration. For these patients disarticulation of the hip or shoulder 
griddle, rotationplasty, femoral or below knee, humeral or other amputations are far more 
appropriate (González-Heranz et al., 1995; Sæter et al., 1996; Wittig et al., 2002; 
Samardziski et al. 2009).  
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a)     b) 
   
a)     b) 
  
c)     d) 
Fig. 5. a) x-ray of high-grade chondroblastic osteosarcoma of right distal femur in a girl of 
17; b) anterior and lateral MRI view of the lesion; c) photo of the resected tumor; d) tumor 
site ready for reconstruction; e, f) reconstructed right femur and knee (Link modular 
endoprosthesis). 
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The current recommendation for detectable metastases is to excise as many lesions as 
technically feasible following surgical treatment of the primary tumor. The survival rate for 
patients can be as high as 60%-75% when both the primary tumor and the solitary lung 
metastasis are adequately resected (Yonemoto et al., 1997; Bacci et al., 2006).  
The rate of surgical site recurrence is 4% to 6% for both limb-salvage and amputations. 
Complications following limb-salvage reconstructions include wound complications, 
infections, mechanical failure, and nonunion. The reported incidence of complications with 
limb-salvage surgical techniques is 4% to 38% (Kotz et al., 2002). 
6.3 Postoperative follow-up 
After chemotherapy, the patient should be closely followed by the orthopedic oncology 
surgeon and the medical oncologist. The patient should be monitored for local recurrence, 
distant or systemic metastases and complications related to reconstruction of the extremity. 
CT scanning of the chest, plain film radiographs of the reconstructed extremity and 
meticulous physical examinations are recommended every three months for the first two 
years and at least every six months from the second year through to the fifth year, and 
subsequently on a yearly basis. Also, annual bone scintigraphy is mandatory for the first 
two years after completion of the chemotherapy. 
 
 
Fig. 6. Scandinavian Sarcoma Group Protocol XIV 
7. Neoadjuvant chemotherapy 
Dramatic changes over the past few decades have occurred with neoadjuvant (preoperative) 
and adjuvant (postoperative) poly chemotherapy protocols. This improved the ability to 
perform safe limb-sparing resection of the tumor in more than 85% of the osteosarcoma 
patients. Today, as reported in the literature, 60-80% of the patients with extremity localized 
non metastatic osteosarcomas are long term survivors. 
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Multidrug neoadjuvant chemotherapy, popularized for patients with osteosarcoma by 
Rosen and later by Jaffe in the late 1970’s, is usually initiated as appropriate after histo-
pathological diagnosis and staging. Neoadjuvant chemotherapy protocols with high-dose 
methotrexate, and cisplatin and doxorubicin dramatically improved long-term survival 
rates in patients with osteosarcoma sensitive to chemotherapy. Using high dose ifosfamide 
or different additional and more aggressive therapeutic agents for less sensitive in 
postoperative chemotherapy (as in: Cooperative Osteosarcomstudiengruppe 96 protocol, 
Scandinavian Sarcoma Group Protocol XIV and European bone over 40 sarcoma study) 
improved the results and overall survival of these patients (Kotz et al., 2002). Because of the 
aggressive nature of the protocols, rescue with Leucoverin (as antidote), bone marrow 
stimulation with Neupogen and renal protection with Uromitexan are essential. Maximal 
hydration followed by diuretic forced renal clearance further improves patient’s 
chemotherapy tolerance. During chemotherapy, antiemetics, including: dexamethasone, 
diphenylhydramine and lorazepam are routinely used in all patients (Bacci et al., 1993; 
Bruland, 1999; Messershmitt et al., 2009).  
7.1 Various neoadjuvant chemotherapy protocols 
There are various poly-chemotherapy protocols (some in regular practice, other in 
experimental phase). Basic science is making continuous advance that may yield more 
specific, less-toxic drugs that will further improve survival rates. The use of high dose 
Ifosfamide or different, additional and more aggressive, therapeutic agents for less sensitive 
osteosarcoma patients in postoperative modern chemotherapy becomes a rule. There are 
many chemotherapy regimens, but most commonly reported are: Cooperative 
Osteosarcomstudiengruppe 96 protocol (COSS 96), Scandinavian Sarcoma Group Protocol 
(SSG) XIV, European bone over 40 sarcoma study (EURO-B.O.S.S/COSS), Italian Sarcoma 
Group protocol (ISG), Sloan-Kettering Center protocol T-10 (SSG III), American Society of 
Clinical Oncology (ASCO) protocol, etc. Introducing more aggressive chemotherapy for 
poor responders, improved the results and overall survival of these patients (Brulnad, 1999; 
Di Caprio & Friedlander, 2003).  
7.2 Effects of neoadjuvant chemotherapy in high-grade non-metastatic osteosarcoma 
of extremities 
Various effects of neoadjuvant therapy, such as: remission of pain, reduction of the size of 
the tumor, sclerosation, pseudo capsule formation, decreasing of neo-vascularisation, tumor 
necrosis and decrease of the elevated alkaline phosphathase and lactate dehydrogenase 
levels are widely reported. After neoadjuvant chemotherapy a clinical and radiological 
response of the tumor has been observed (Bacci et al., 1993). There was reduction, or more 
often complete remission of pain. This was usually followed with normalization of serum 
alkaline phosphathase and lactate dehydrogenase levels (if elevated). Bacci further reported 
an increased density (as seen on Fig. 7b) by the bone lesion on plain radiographs associated 
with decreased vascularity on angiograms.  
Clinical and radiographic reduction in tumor size was observed in more than half of the 
patients. This was more due to a decrease of the surrounding inflammatory and reactive 
tissue than to an actual reduction in tumor size. Bacci reported that reduction in vascularity, 
was the one, most predictable criterion to assess the response of the tumor after neoadjuvant 
chemotherapy. Neoadjuvant chemotherapy may also decrease the size of the primary tumor 
www.intechopen.com
Effects of Neoadjuvant Chemotherapy in  
High-Grade Non-Metastatic Osteosarcoma of Extremities 
 
225 
(Fig. 7) by reducing its neo-vascularity and promoting tumor demarcation from surrounding 
tissue with pseudo-capsule (Fig 5b). This makes limb-salvage surgery technically more 
feasible, even if a marginal resection is obtained (Messershmitt et al., 2009). 
 
 
 
     
a)   b)   c) 
Fig. 7. a) Fifteen years old female osteosarcoma patient with pathological fracture of the 
left proximal humerus at the first presentation. The patient had preoperative 
(neoadjuvant) chemotherapy with Swedish Sarcoma Protocol XIV. b) Excellent response 
(>90% tumor necrosis) with sclerosation after neoadjuvant chemotherapy (arrow shows 
the site of the pathological fracture). c) Radiograph of the humerus after wide resection of 
the osteosarcoma, and first stage reconstruction of the bone with intramedullary rod and 
bone cement. 
The primary goal of neoadjuvant chemotherapy is to treat undetectable (or micro) 
metastases. It is reasonable to believe that neoadjuvant chemotherapy may decrease the risk 
of spreading viable tumor cells after biopsy, and therefore, decrease the possibility of distant 
metastases and of local recurrence. This is only possible with optimal serum concentration 
of methotrexate (at least 1000 µM) at the end of a 6 hour infusion. All of these advantages of 
neoadjuvant chemotherapy enables more options for wide or near-marginal resection of the 
tumor and for a limb-sparing surgery (Bruland & Phil, 1999).  
7.3 Macedonian long-term follow-up experiences with the effects of neoadjuvant 
chemotherapy in patients with extremity localized high-grade osteosarcoma 
Following the “wave of modern” poly-chemotherapy, in the period 2000-2008, a prospective 
study was done at the University Clinic for Orthopedic Surgery and Institute of Radiology 
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and Oncology in Skopje. In this period, 47 patients with high-grade osteosarcoma, were 
treated (Samardziski et al., 2009a).  
Selection of patients for neoadjuvant chemotherapy and limb-salvage surgery was based on 
the following criteria:  
Inclusion criteria: 
- histopathologically proven high-grade osteosarcoma (grade III or IV);  
- primary localization on the extremities, with no evidence of lung or other metastases; 
- patient age between 8 and 65 years; normal hepatic and renal function;  
- leukocyte count over 3.0×109/L and platelet count over 100×109/L;  
- neoadjuvant chemotherapy was introduced no longer than 1 month after histological 
diagnosis of osteosarcoma. 
Exclusion criteria: 
- patients with central localization of osteosarcoma (e.g. pelvis, vertebra);  
- evidence of lymphatic or haematogenous metastases at the time of diagnosis;  
- patients under 8 years or older than 65 years;  
- pregnant or nursing women. 
According to the exclusion criteria, 8/47 patients were excluded, owing to lung metastases at 
first presentation or pelvic localization. Another 10/39 patients were excluded from the study 
due to primary indication for ablative surgery (amputation or disarticulation). Seventy five 
percent of the patients (29/39) were treated with limb-sparing surgery (Table 2). Fourteen 
(48%) patients were male and 15 (52%) were female. The mean age was 23.4 ± 14.5 years 
(range 8-63). Mean follow-up was 49.9 ± 23.1 months (range 23-108).  
All patients received to the Scandinavian Sarcoma Group XIV neoadjuvant chemotherapy 
protocol (SSG XIV). Patients received 2 cycles of preoperative chemotherapy (high dose 
methotrexate 1200 mg/m2, cisplatin 45 mg/m2/day ×2 days, and doxorubicin 75 mg/m2), 
(Fig. 6).  
After resection, a detailed histopathological assessment of the specimen was done to 
determine the extent of necrosis of the tumor tissue. Considering the percentage of necrotic 
tumor tissue, patients were classified into two groups. The first group experienced good 
response to chemotherapy (>90% necrosis of the tumor). The second group had a poor 
response to chemotherapy (>10% viable tumor). Regarding good or poor response of the 
tumor to chemotherapy, patients followed different branches of the protocol (Fig. 6). All 29 
patients received 3 courses of postoperative chemotherapy (the same as preoperative). 
Patients with poor response received 3 more cycles of chemotherapy with high dose 
ifosfamide (2000 mg/m2/ day ×5 days plus Mesna) every 3 weeks (Fig. 6). Histopathological 
assessment of the specimen did not only identify the extent of tumor necrosis, but 
information on tumor-free margins, too. 
We have analyzed the following parameters of the clinical and radiological data after 
neoadjuvant chemotherapy: age, gender, time of follow-up, necrosis of the resected tumor 
after neoadjuvant chemotherapy (poor or good response), decrease of pain, decrease in 
tumor diameter, tumor pseudo-capsule seen on MRI, sclerosis seen on radiographs or CT, 
local recurrence and metastases (Table 2). 
Response to neoadjuvant chemotherapy was good (more than 90% necrosis of the tumor) 
in 16/29 patients (55.2%). The examinees with good response to neoadjuvant therapy had 
significantly longer overall survival time than the patients with poor response (fig. 8). Ten 
percents of the patients with poor response survived for more than 65 months, while 58% 
of the patients with good response survived for more than 100 months (Log-Rank 
test=3,74 p=0.0002). 
www.intechopen.com
Effects of Neoadjuvant Chemotherapy in  
High-Grade Non-Metastatic Osteosarcoma of Extremities 
 
227 
Patie-
nt 
No. 
Age 
(y.) 
Gender 
Follow-
up (m.) 
Response 
to neoa-d. 
chemoth. 
Decrease 
of pain 
Decrease 
in 
diameter 
Pseudo-
capsule 
Sclerosis 
Recurre-
nce 
(m.) 
Metasta-
ses 
(m.) 
Deceased 
after 
(m.) 
1 25 M 30 P 0 1 0 0 0 22 30 
2 13 M 32 P 1 1 1 0 0 27 32 
3 23 M 50 G 1 1 U 1 0 29 - 
4 16 F 44 P 1 1 1 1 0 38 44 
5 15 F 68 G 1 1 1 1 50 57 68 
6 14 M 51 G 1 1 1 1 0 0 - 
7 8 F 50 G 1 1 1 1 29 43 50 
8 13 M 45 G 1 1 1 1 0 0 - 
9 16 F 54 P 1 1 1 1 0 36 54 
10 17 F 23 P 0 0 0 0 6 12 23 
11 54 F 38 P 1 1 U 1 0 0 38 
12 14 F 98 G 1 1 1 1 0 0 - 
13 63 M 106 G 1 1 1 1 96 100 106 
14 17 M 67 P 1 0 1 1 54 60 67 
15 16 M 59 G 1 1 1 0 0 0 - 
16 20 F 54 P 1 1 1 0 0 46 54 
17 20 F 47 G 1 1 1 1 0 0 - 
18 16 M 10 P 0 0 0 0 2 4 10 
19 39 F 61 P 1 0 1 1 53 57 61 
20 14 M 26 P 0 0 0 0 19 19 26 
21 8 M 40 G 1 1 1 0 0 0 - 
22 44 F 59 G 1 1 U 1 0 0 - 
23 14 M 40 G 1 1 1 1 0 30 40 
24 44 F 35 P 0 1 0 0 21 28 35 
25 15 F 108 G 1 1 1 0 0 0 - 
26 15 M 27 P 0 0 0 0 2 11 27 
27 48 F 43 G 1 1 1 1 0 0 - 
28 24 F 33 G 1 1 1 1 18 0 - 
29 34 M 51 G 1 1 0 1 35 45 51 
M: male; F: female; G: good response after neoadjuvant chemotherapy (necrosis >90% of the tumor); P: 
poor response after neoadjuvant chemotherapy (>10% viable tumor); U -unknown or missing data; 1-
yes; 0-no or none. 
Table 2. Clinical data of patients with high-grade osteosarcoma of the extremities, treated 
with neoadjuvant chemotherapy. 
Local recurrence appeared in 17/29 patients (58.6%). The examineеs without local relapse 
had significantly longer overall survival time than the examined persons with no relapse. 
Ten percent of the patients with relapse survived more than 100 months, while 48% of the 
examined with no local relapse were alive even after 100 months (Log-Rank test p=0.0002). 
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Most of the tumor relapses were seen in the patients by 22 months after surgery. The 3 
patients with early local recurrences had secondary extirpation of the relapsed tumor and 
one of them had to be amputated.  
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Fig. 8. Response of the patients after neoadjuvant chemotherapy treated with SSG XIV 
chemotherapy protocol. 
Lung metastases appeared in 18/29 patients or 62.1%. The examinees with metastases had 
significantly shorter overall survival time than the metastasis-free patients. Four percent 
of the examined patients with metastases survived longer than 100 months, while 90% of 
the examined with no metastases were alive even after 100 months (Log-Rank test 
p=0.0002). 
Plain radiograph or CT-scan sclerosis of the tumor after neoadjuvant chemotherapy was 
seen in 18/29 patients (62.1%). Pseudo-capsule was seen in 19/29 patients (65.5%), but in 
3/29 (10.3%) MRI imaging showed inconclusive data. Cystic necrosis after neoadjuvant 
chemotherapy was seen in 14/29 patients (48.3%). Inconclusive results for cystic necrosis 
were found in 3 and data was missing for 1 patient.  
Up to date 10/29 patients (34.5%) are disease or event free. Mean survival time of the 
patients was 53 months, and 20% of the examinees survived longer than 60 months (Fig. 9). 
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Fig. 9. Disease and event free survival time of the patients with extremity localized high-
grade osteosarcoma treated with SSG XIV neoadjuvant chemotherapy protocol and surgery. 
Using high dose ifosfamide for poor responders in postoperative chemotherapy should 
improve the results and overall survival time of these patients. If treatment and 
management principles of high-grade osteosarcoma are followed, limb-sparing with 60-80% 
survival rates could be achieved. Our preliminary results are slightly different from those 
published in the literature. There was a significantly different overall survival time in our 
study between the group of patients with good response to neoadjuvant chemotherapy 
compared to the group of patients with bad response. Furthermore, overall survival time in 
our group of patients was shorter than the time reported in the literature. In spite of the 
recorded differences in the results, the treatment regimen with neoadjuvant chemotherapy 
is promising and encouraging. 
7.4 Toxic effects of neoadjuvant chemotherapy regimen 
Most often hematologic toxicity is seen after chemotherapy. Various authors report Grade 3 
or Grade 4 hematologic toxicity in 10-15% of the treated patients. Severe leucopenia and/or 
thrombocytopenia are the two conditions for readmitting patients in hospital. In that case 
Neupogen or Leucoverin rescue treatment is beneficial (Bacci & Picci, 1994). 
Most of these patients with myelotoxicity have fever and microbiologically proven 
bacteremia during their granulocytopenic phase. Wide spectrum antibiotics in the beginning 
and specific antibiotics after microbiological assessment are necessary. 
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Cardiotoxicity is less often reported in patients with neoadjuvant chemotherapy. 
Unfortunately this side effect of the treatment is most serious and cardiopathy following the 
treatment may become a chronic life treating condition.  
Due to general toxic effects to the human body and profound systemic reaction of all organs 
and systems to chemotherapeutics, sickness, malaise and weakness are general side effects. 
A common problem is abdominal pain associated with mild asscites, easily visualised on 
ultrasonography. Therefore antiemetics and corticosteroids, including dexamethasone, 
diphenylhydramine and lorazepam are routinely used in all patients (Bacci et al., 1993; 
Bruland, 1999; Messershmitt et al., 2009).  
Skin necrosis, tender local swelling, inflammation, due to local intra-arterial cisplatin or 
venous trombophlebitis occurres in some patients. This lesions usually do not cause a major 
problem and usually heal in 2-3 weeks with pigmented scars. 
8. Discussion  
Prior to the introduction of chemotherapy, when amputation was the primary treatment for 
patients with osteosarcoma, the predicted long-term survival was 15-20%. Dismal survival 
rates were presumably attributable to pulmonary metastatic disease, whether clinically 
obvious or occult (Enneking, 1975). Survival rates dramatically increased during 1970’s and 
1980’s with the pioneering work of Rosen and Jaffe. Currently, long-term survival rates are 
60% to 70% for patients with localized osteosarcoma and for extremity localized up to 80% 
(Meyers et al., 2008). Despite the use of modern neoadjuvant chemotherapy the 10-year 
survival rates decline significantly to 20% in patients with clinically detectable metastases. 
Most of the patients ultimately die because of respiratory failure caused by the metastatic 
burden (Bacci et al., 2008; Messerschmitt et al., 2009; Samardziski et al., 2009a). Excluding 
high-grade surface osteosarcoma, which has similar prognosis to that of conventional 
osteosarcoma, the surface (parosteal and periosteal) osteosarcoma variants have the best 
prognosis of all. The 10-year survival rates for this group of patients is up to 85% 
(Samardziski et al., 2009b).  
The site of the lesion has prognostic importance. The best survival rates are expected in 
patients with appendicular localization of the osteosarcoma. Central localization (pelvis, ribs 
and vertebrae) are less common sites of osteosarcoma, and have poorest prognosis. 
Osteosarcoma of the jaw is associated with an especially good prognosis, whereas 
osteosarcoma involving the skull has a very poor prognosis (Unni, 1998; Yu & Wang, 2009). 
Badly planned and ill preformed biopsy can complicate the final surgery and may decrease 
survival rates due to local spreading or risk for early metastatic disease (Mankin et al., 1982; 
Campanacci, 1999).  
The overall treatment results in high-grade osteosarcoma are less impressive than widely 
presumed. Whereas classical osteosarcoma survival has indeed increased, in other 
subgroups, comprising more than 40% of the entire osteosarcoma population , the 
prognosis has been modestly improved. Today still more than half of an unselected 
osteosarcoma population eventualy succumbs to the disease, despite the current 
multimodal primary treatment as well as second-line chemotherapy and surgical 
metastatectomies (Bruland, 1999). 
Neoadjuvant chemotherapy enables limb-sparing in the majority of patients with extremity 
localised ostesarcoma. During the past 20 years dramatic advances have been made in the 
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treatment of non-metastatic osteosarcoma in terms of cure rate and quality of life for survivors. 
These advances are due mainly to the development of effective adjuvant and neoadjuvant 
chemotherapeutic regimens. Reports on the progress and controversies in the treatment of 
osteosarcoma occurred with respect to the construct, expirimental design and interpretation of 
the studies. Never the les, this sdudyes led to remarkable results (Bacci, 2008).  
8.1 Prognosis 
Poor prognostic factors for patients with osteosarcoma include metastases at first 
presentation, extremely large primary tumor, increased alkaline phosphatase and lactate 
dehydrogenase levels, poor response to neoadjuvant chemotherapy, tumor discontinuous 
from bone, pathologic fractures and lymph node involvement (Longhi, et al. 2006). Despite 
current surgical and chemotherapeutic treatment regimens, 30% to 40% of osteosarcoma 
patients experience relapse within 3 years of treatment. Pulmonary recurrence is most 
common secondary to micro-metastatic disease. Regardless of poor prognosis, repeated 
tumor excisions can be performed (of primary site or metastatic one), because many studies 
have shown improved survival rates (Yonemoto, 1997; Bacci et al., 2001). The role of 
“second-line” chemotherapy regimen remains controversial because no standard regimen 
exists for the recurrence of the tumor. 
The evaluation variables influencing systemic and local recurrence and final outcome are 
extremely important in defining risk-adapted treatments for patients with nonmetastatic 
osteosarcoma of the extremity. Upon multivariate analysis, age ≤ 14 years, high serum levels 
of alkaline phosphatase, tumor volume >200 mL, a dual-drug regimen chemotherapy, 
inadequate surgical margins, and poor histologic response to treatment maintained 
independent prognostic values on the outcome of nonmetastatic osteosarcoma of the 
extremities. These factors must be considered when deciding risk-adapted treatments for 
osteosarcoma patients (Pochanugool, 1997; Bacci, 2006; Yu & Wang, 2009). Amputation 
remains the indicated treatment when these factors are taken into consideration or tumor 
resection to disease-free margins leaves a nonfunctional limb (Enneking, 1975; Di Caprio & 
Friedlander, 2003). 
8.2 Future considerations 
A logical development of chemotherapy was introduction of local (or loco-regional) intra-
arterial methods of chemotherapy. The obvious limitations are complicated intra-arterial 
techniques of application of chemotherapeutics and uncontrolled risk of tissue necrosis. 
Intra-arterial administration of cisplatin has been investigated for achieving improved 
histological response following chemotherapy. Since the originalr attempts to administer 
intra-arterial cisplatin from the 1980’s, major advance in imaging and surgical techniques 
have improved the results and made it easier and safer. Reported studies demonstrate an 
increase in long-term survival up to 93%. Thus, a consensus on the routine use of intra-
arterial chemotherapy does not exist (Jaffe, 1989; Bacci et al., 2001; Messershmit et al., 2009). 
Basic science is making continuous advance in molecular mechanisms and biologic 
pathways that may yield more specific, less-toxic drugs that will further improve survival 
rates. Inhibition of tyrosine kinase signaling is known to regulate cell growth, cell 
proliferation, angiogenesis, and apoptosis and is an area of current interest (Messershmit et 
al., 2008). Liposomal muramyl tripeptide phosphatidilethanolamine (L-MTP-PE) is a 
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promising drug in clinical trial that functions to stimulate the formation of tumoricidal 
macrophages (Meyers et al., 2008). 
9. Conclusion  
With advances in neoadjuvant chemotherapy, radiographic imaging, and reconstructive 
surgery, most patients with osteosarcoma can now be offered limb-sparing treatment. A 
multidisciplinary approach in diagnosis and treatment is mandatory. Surgical resection with 
wide margins after neoadjuvant and adjuvant chemotherapy after surgery is a current 
standard of care. Osteoarticular allografts, modular prostheses, or composites of these two 
approaches form the basis for most current reconstructions. However, amputation still plays 
an important role and offers a standard to which other approaches must be compared. Basic 
science is making continuous advance in molecular mechanisms and more specific, less-
toxic drugs will further improve survival rates. Current research into the cell biology of 
osteosarcoma may lead to improved and more target-selective treatment with the intent of 
improved overall survival.  
Applying neoadjuvant chemotherapy followed by appropriate surgery requires responsible, 
trained and highly engaged medical staff. If treatment and management principles of high-
grade osteosarcoma with neoadjuvant therapy are followed, long-term 60-80% overall 
survival rates could be easily achieved. 
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